12-55724028-G-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong
The NM_002905.5(RDH5):c.712G>T(p.Gly238Trp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000281 in 1,611,424 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G238A) has been classified as Likely pathogenic.
Frequency
Consequence
NM_002905.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RDH5 | NM_002905.5 | c.712G>T | p.Gly238Trp | missense_variant | 4/5 | ENST00000257895.10 | NP_002896.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RDH5 | ENST00000257895.10 | c.712G>T | p.Gly238Trp | missense_variant | 4/5 | 1 | NM_002905.5 | ENSP00000257895.6 | ||
ENSG00000258311 | ENST00000550412.5 | c.*2322G>T | 3_prime_UTR_variant | 4/4 | 2 | ENSP00000447650.1 |
Frequencies
GnomAD3 genomes AF: 0.000197 AC: 30AN: 152212Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000219 AC: 54AN: 246894Hom.: 0 AF XY: 0.000224 AC XY: 30AN XY: 133976
GnomAD4 exome AF: 0.000290 AC: 423AN: 1459094Hom.: 0 Cov.: 31 AF XY: 0.000284 AC XY: 206AN XY: 725916
GnomAD4 genome AF: 0.000197 AC: 30AN: 152330Hom.: 0 Cov.: 32 AF XY: 0.000175 AC XY: 13AN XY: 74496
ClinVar
Submissions by phenotype
Pigmentary retinal dystrophy Pathogenic:5
Pathogenic, no assertion criteria provided | research | Sharon lab, Hadassah-Hebrew University Medical Center | Jun 23, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics and Genomics, Karolinska University Hospital | May 02, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 18, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | May 22, 2022 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.021%). Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID:11675386). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.92; 3Cnet: 0.72). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000008003). The variant has been reported to co-segregate with the disease in at least one similarly affected relative/individual in the same family or similarly affected unrelated family (PMID:10369264, 10617778). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 01, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with tryptophan, which is neutral and slightly polar, at codon 238 of the RDH5 protein (p.Gly238Trp). This variant is present in population databases (rs62638191, gnomAD 0.05%). This missense change has been observed in individuals with fundus albipunctatus (PMID: 10369264, 10617778). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 8003). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RDH5 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects RDH5 function (PMID: 11675386). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | May 01, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 18, 2018 | Published functional studies demonstrate a damaging effect; variant causes reduced enzymatic activity and different staining pattern with a strong perinuclear localization for G238W mutant cells compared to wild type (Liden et al., 2001; Yamamoto et al., 1999); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 31456290, 32141364, 17476461, 20829743, 10617778, 18949499, 10369264, 11675386) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Nov 29, 2016 | - - |
Fundus albipunctatus, autosomal recessive Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 30, 1999 | - - |
See cases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Jul 15, 2020 | ACMG classification criteria: PS3, PS4, PM2, PP1 - |
RDH5-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 29, 2024 | The RDH5 c.712G>T variant is predicted to result in the amino acid substitution p.Gly238Trp. This variant has been reported in the homozygous and compound heterozygous states in individuals with autosomal recessive fundus albipunctatus (Yamamoto et al. 1999. PubMed ID: 10369264; Gonzalez-Fernandez et al. 1999. PubMed ID: 10617778). Functional studies have shown that the p.Gly238Trp substitution reduces enzyme activity by 90% (Yamamoto et al. 1999. PubMed ID: 10369264; Lidén et al. 2001. PubMed ID: 11675386). This variant is reported in 0.045% of alleles in individuals of Latino descent in gnomAD. Given the evidence, we interpret c.712G>T (p.Gly238Trp) as pathogenic. - |
Retinal dystrophy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg | Jan 01, 2021 | - - |
Congenital stationary night blindness Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Ophthalmic Genetics Group, Institute of Molecular and Clinical Ophthalmology Basel | Jul 24, 2023 | Clinical significance based on ACMG v2.0 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at